Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Depreciation and Depletion (2020 - 2023)

Rein Therapeutics (RNTX) has disclosed Depreciation and Depletion for 4 consecutive years, with $12000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Depreciation and Depletion fell 90.4% to $12000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $49000.0, a 71.01% decrease, with the full-year FY2023 number at $49000.0, down 71.01% from a year prior.
  • Depreciation and Depletion was $12000.0 for Q4 2023 at Rein Therapeutics, roughly flat from $12000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $125000.0 in Q4 2022 to a low of $2000.0 in Q1 2021.
  • A 4-year average of $33466.7 and a median of $14000.0 in 2020 define the central range for Depreciation and Depletion.
  • Biggest YoY gain for Depreciation and Depletion was 960.0% in 2021; the steepest drop was 97.14% in 2021.
  • Rein Therapeutics' Depreciation and Depletion stood at $10000.0 in 2020, then soared by 960.0% to $106000.0 in 2021, then grew by 17.92% to $125000.0 in 2022, then plummeted by 90.4% to $12000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Depreciation and Depletion are $12000.0 (Q4 2023), $12000.0 (Q3 2023), and $12000.0 (Q2 2023).